MHRA-100409-PIP01-21-M01 (update)

Key Facts

Active Substance
Active Substance:
  • autologous dendritic cells pulsed with autologous tumour cell lysate
Invented Name
Not yet available
PIP Number MHRA-100409-PIP01-21-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Cell suspension for injection
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of high grade glioma
Route(s) of administration
Route(s) of administration:
  • Intradermal use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):autologous dendritic cells pulsed with autologous tumour cell lysate.pdf
Published Date 19/12/2023